Agencia Española de Medicamentos y Productos Sanitarios

C/Campezo 1, Edificio 8
28022 – Madrid
España
(Reference Member State)

MUTUAL RECOGNITION PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

HIPRAVIAR B1

CORREO ELECTRÓNICO

mresvet@aemps.es

C/ CAMPEZO, 1 – EDIFICIO 8
28022 MADRID
TEL: 91 822 54 01
FAX: 91 822 5443

MODULE 1

PRODUCT SUMMARY

EU Procedure number	ES/V/0275/001/MR
Name, strength and pharmaceutical form	HIPRAVIAR B1, lyophilisate for suspension for chickens
Applicant	LABORATORIOS HIPRA, S.A., Avda. la Selva, 135 17170 AMER (Girona) Spain
Active substance(s)	Live attenuated Newcastle Disease Virus, strain B1
ATC Vet code	QI01AD06
Target species	Chickens
Indication for use	For active immunisation of broilers, hens and future layers and breeders for the prevention of clinical signs and deaths caused by Newcastle disease

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies website (http://www.hma.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Mutual Recognition application in accordance with Article 12.3 of Directive 2001/82/EC as amended.
Date of completion of the original mutual recognition procedure	23/11/2017
Date product first authorised in the Reference Member State (MRP only)	16/02/2011
Concerned Member States for original procedure	DE

I. SCIENTIFIC OVERVIEW

***For public assessment reports for the first authorisation in a range**:*

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.
The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Composition

The vaccine is presented as a lyophilisate for suspension.

The product contains $10^{6.5}$ – $10^{7.7}$ EID_{50} / Dose of live attenuated Newcastle disease virus strain B1 (EID_{50} = 50 % infective dose in chicken embryos). It does not contain neither adjuvant nor preservative. As the product can be used by using the oculo-nasal route, a colorant is included in the specific solvent for this route in order to differentiate vaccinated and unvaccinated birds. The solvent is Patent blue V (E-131).

The container/closure system for the lyophlisate are neutral glass type I glass vials. The particulars of the containers and controls performed are provided and conform to

the regulation. The solvent (only for the oculo-nasal route) is filled into plastic bottles which are in accordance with Ph. Eur.

The choice of the, vaccine strain and formulation as well as the absence of preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

The product is manufactured in accordance with the European Pharmacopoeia and relevant European guidelines.

C. Control of Starting Materials

The active substance is the live attenuated Newcastle disease virus, strain B1 (also called Hitchner strain), established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Starting materials of non-biological origin used in production comply with pharmacopoeia monographs.

The master and working seeds have been produced according to the Seed Lot System as described in the relevant guideline.

D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

E. Control tests during production

The tests performed during production are described and the results of 3 consecutive runs, conforming to the specifications, are provided.

F. Control Tests on the Finished Product

The tests performed on the final product conform to the relevant requirements; any deviation from these requirements is justified. The tests include in particular general characteristics of the product (appearance, solubility and packaging), identity of the active substance, viral titre, bacterial and fungal contamination, absence of mycoplasmas, tests for extraneous agents and residual humidity. For the solvent, the appropriate test are performed: appearance, pH, sterility, volume control and packaging.

The demonstration of the batch to batch consistency is based on the results of 3 batches produced according to the method described in the dossier. Other supportive data provided confirm the consistency of the production process.

G. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

After dilution or reconstitution according to directions the vaccine should be used immediately

H. Genetically Modified Organisms

J. Other Information

As this is an avian virus, specific Eur. Ph. monographs have been fulfilled and control methods and validations have been provided.

III. SAFETY ASSESSMENT

The vaccine batches used in the safety studies are production batches manufactured according to the part IIB of the dossier.

Laboratory trials

The safety of the administration of one dose and an overdose in the target animal is demonstrated in appropriate laboratory trials. The investigation was performed according to the recommendations of Directive 2001/82/EC as amended and the relevant guidelines. Very rarely, respiratory symptoms may occur in vaccinated birds at 5-7 days post vaccination and this warning is stated in the SPC.

As HIPRAVIAR-B1 is intended for future layers and breeders before the onset of the productive period, the applicant performed a specific trial to assess the safety of the vaccine in hens at an appropriate production stage.

There are no data suggesting that this product might adversely affect the immune system of the vaccinated animal or its progeny therefore a specific study was not carried out.

For the live strain included in the vaccine, specific studies were carried out to describe the spread, dissemination, reversion to virulence and biological properties. The results of the trials are satisfactory and the SPC contains the appropriate special warnings and precautions. No specific study has been performed about recombination or genomic reassortment of the vaccine taking into account the large amount of studies on this virus (specifically on strain B1) and the absence of recombination reports for HIPRAVIAR B1, the applicant's conclusion can be considered acceptable.

No specific assessment of the interaction of this product with other medicinal product was made. Therefore, an appropriate warning in the SPC is included.

Field studies

One field trial was performed.

IV. EFFICACY

IV.B Clinical Studies

Laboratory Trials

The efficacy of the product has been demonstrated in a laboratory study in accordance with the relevant requirements which show that the vaccine can be used for the prevention of clinical signs and deaths caused by Newcastle disease.

Scientific bibliography provided by the applicant supports the duration of immunity. A specific Duration of Immunity study will be performed and the Applicant has signed the commitment.

The claim proposed by the applicant has been satisfactorily addressed. Nevertheless, as it has been stated at the beginning of the Assessment Report, it would be desirable that according to current QRD and taking into account the results of the laboratory trial, the wording of section 4.2 of SPC might be more precise.

The challenge strain used in the laboratory trial and the challenge virus dose comply with the requirements of the Ph. Eur. monograph 0450.

Field Trials

An outbreak of Newcastle disease was used to perform a field trial that showed that birds vaccinated developed better production parameters than those not vaccinated.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website (http://www.hma.eu/vmriproductindex.html).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.